



Soliqua® / Suliqua®

**Externally-Sponsored Research (ESR)
Areas of Interest**



Soliqua® / Suliqua® ESR Areas of Interest

Areas of Interest	Gap/Unmet Need Addressed
Overall clinical benefit of timely comprehensive glycemic management in the diabetes disease process in short and long term.	Demonstrate the importance of FPG-PPG in timely glycemic control in the treatment of T2DM
Assessment of clinical benefit of treatment simplification (Soliqua vs. complex therapies) including patient experience, adherence and satisfaction.	De-intensification of complex insulin therapies
Switch from MDIs such as free combination or premix to FRC/Soliqua in real life.	
Assessment of glycemic control with technological support such as smart pen, titration tool, and CGM focusing impact on clinical & patient reported outcomes.	Lack of technology support with Soliqua

sanofi

•

Sanofi – TOUJEO®

ESR Areas of Interest

•

24.Jul.23

Toujeo Areas of Interest

Areas of Interest	Gap/Unmet Need Addressed
Novel approaches to assess impact of titration period	• Optimal titration and early glycemic control on short- and long-term outcomes • Use and support of titration tools/education period/telemedicine
Real World Evidence (RWE)	• Special populations • Pediatrics • Renal impairment • At hypo risk populations (elderly, exercising, fasting, and patients with CV comorbidities) • CGM data on time in range
Treatment pathways	• With prior use of weekly or oral GLP1-RA • With prior use of post SGLT2 inhibitor • With prior use of post TZP
Patient Reported Outcomes (PRO)	• Interplay of insulin-based therapies and connectivity, diabetes management tools